BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Exp Med. Sep 20, 2026; 16(3): 120531
Published online Sep 20, 2026. doi: 10.5493/wjem.120531
Figure 2
Figure 2 Management options in preventing osteoclast stimulation from the pathological activation of the receptor activator of NF-kappaB/receptor activator of NF-kappaB ligand/osteoprotegerin axis. RANKL: Receptor activator of NF-kappaB ligand; RANK: Receptor activator of NF-kappaB; OC: Osteoclast; OB: Osteoblast; IGF: Insulin-like growth factor; TGF: Transforming growth factor. Created in BioRender (Supplementary material).


Write to the Help Desk